Home > Insider Trading > Filing (0001410939-23-000007)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1410939	Iveric Bio Inc.	ISEE	Pharmaceutical Preparations (2834)	208185347

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1703623	Francis David Carroll	C/O Iveric Bio, Inc. 8 Sylvan Way Parsippany NJ 07054	Svp, Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-01-02	8,750	$0.00	72,074	No	4	M	Direct
Common Stock	Disposition	2023-01-03	3,602	$20.06	68,472	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2023-01-02	8,750	$0.00	8,750	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
26,250			No	4	M	Direct

Footnotes

Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of the restricted stock units on January 2, 2023.
The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $19.91 to $20.56 on January 3, 2023 on behalf of a group of employees of the Registrant to satisfy the payment of withholding tax liability of such employees. The Reporting Person undertakes to provide upon request by the staff of the Securities Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
On December 16, 2021, the Reporting Person was granted 35,000 restricted stock units, which vests with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026), subject to continued employment with the Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan.